Valuation: Cogstate Limited

Market Cap 593M 418M 375M 346M 314M 585M 39.81B 4.14B 1.65B 20.88B 1.57B 1.54B 66.02B P/E 2027 *
27.3x
P/E 2028 * 21.2x
Enterprise Value 528M 373M 334M 309M 279M 521M 35.45B 3.69B 1.47B 18.6B 1.4B 1.37B 58.79B EV / Sales 2027 *
4.85x
EV / Sales 2028 * 4.07x
Free-Float
56.43%
Yield 2027 *
1.45%
Yield 2028 * 1.77%
1 day+0.29%
1 week-3.35%
Current month+1.47%
1 month+4.53%
3 months+40.65%
6 months+41.22%
Current year+53.10%
1 week 3.35
Extreme 3.35
3.61
1 month 3.23
Extreme 3.23
3.98
Current year 2.01
Extreme 2.01
3.98
1 year 1.75
Extreme 1.75
3.98
3 years 0.8
Extreme 0.795
3.98
5 years 0.8
Extreme 0.795
3.98
10 years 0.16
Extreme 0.155
3.98
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 1999-12-16
Chief Executive Officer - 2005-11-30
Director of Finance/CFO - 2021-01-31
Director TitleAgeSince
Director/Board Member - 2011-02-28
Chairman 67 2009-11-02
Director/Board Member - 2017-01-19
Date Insider Type Main position Quantity % Market Cap. Importance
5/20/26 Buy

Director

3,600 0.0021%
5/20/26 Buy

Director

430 0.0003%
4/15/26
Myer & Myer Pty Ltd.
SellCompany 9,974,569 5.8334%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-3.35% - - 414M
Average +0.29%
Weighted average by Cap. +0.29%

Financials

2027 *2028 *
Net sales 109M 76.9M 68.91M 63.66M 57.65M 108M 7.32B 761M 303M 3.84B 288M 282M 12.13B 125M 88.43M 79.24M 73.2M 66.29M 124M 8.41B 875M 349M 4.41B 331M 325M 13.95B
Net income 21.8M 15.37M 13.78M 12.73M 11.52M 21.5M 1.46B 152M 60.63M 767M 57.63M 56.42M 2.43B 27.77M 19.59M 17.55M 16.22M 14.68M 27.4M 1.86B 194M 77.25M 978M 73.43M 71.89M 3.09B
Net Debt -64.95M -45.8M -41.05M -37.92M -34.34M -64.06M -4.36B -453M -181M -2.29B -172M -168M -7.23B -82.52M -58.2M -52.15M -48.18M -43.63M -81.4M -5.54B -576M -230M -2.9B -218M -214M -9.18B
Projected Income Statement - Annual - Cogstate Limited
Logo Cogstate Limited
Cogstate Limited is a neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Its principal activities are the creation, validation, and commercialization of digital brain health assessments; and design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Administration. In the Clinical Trials segment, the technology and associated services are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical, and biotechnology companies. In the Healthcare segment, the technology and associated services are being developed as a tool for primary care physicians and/or hospitals to assess cognitive decline.
Employees
160
Date Price Change Volume
26-10-28 A$3.450 0.00% 10,662
26-10-28 A$3.450 +0.88% 140,204
26-10-27 A$3.420 -1.44% 62,590
26-10-26 A$3.470 -0.29% 641,081
26-10-23 A$3.480 -3.33% 848,460
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Cogstate Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.450AUD
Average target price
4.497AUD
Spread / Average Target
+30.34%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cogstate Limited